BofA raised the firm’s price target on Calumet (CLMT) to $28 from $24 and keeps a Buy rating on the shares. A combination of margin momentum and catalysts that could contribute hundreds of millions in additional EBITDA “calls for significant remaining upside to biofuels stocks from here,” the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLMT:
- Calumet price target raised to $24 from $20 at Goldman Sachs
- Calumet Amends Credit Agreement, Extends Maturity to 2031
- Calumet price target raised to $19 from $18 at TD Cowen
- Calumet price target raised to $24 from $23 at BofA
- Elliott Backs Private Hypersonic Firm as U.S. Defense Spending Accelerates